|Bid||18.75 x 800|
|Ask||19.50 x 1200|
|Day's Range||17.92 - 18.98|
|52 Week Range||11.00 - 20.95|
|Beta (5Y Monthly)||0.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2020 - Apr 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.69|
VICTORIA and UTRECHT, The Netherlands , Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced that its wholly owned subsidiary U-Protein Express BV signed a long-term lease contract for the new multi-tenant building for life sciences "Accelerator" at the Utrecht Science Park ( Utrecht, The Netherlands ). In addition to accommodating large biotechnology companies, the new building will offer space to companies that want to accelerate their development.
— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Merus N.V. (NASDAQ:MRUS) last week reported its latest quarterly results, which makes it a good time for investors to...
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing.
Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Merus N.V. (NASDAQ:MRUS). Is Merus N.V. (NASDAQ:MRUS) a buy right […]
Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of $14.50 per share, before underwriting discounts and commissions. Merus also granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $68.9 million, excluding any exercise of the underwriters’ option to purchase additional common shares.
Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of its common shares at the public offering price, on the same terms and conditions. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Merus N.V. (MRUS), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced initial clinical data for three patients with cancers harboring NRG1 fusions treated with MCLA-128 through an Early Access Program (EAP), and provided an overall update on the MCLA-128 clinical programs. Data on the three EAP patients were presented today by study investigators at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Investigators from Memorial Sloan Kettering Cancer Center (MSKCC) provided a summary and initial data concerning the treatment of three cancer patients harboring NRG1 fusions with MCLA-128 at 750 mg administered intravenously every other week. These patients’ NRG1 gene fusions were identified using RNA-based sequencing.
UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing.
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
UTRECHT, The Netherlands, Aug. 19, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.